The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases

Immunobiology

Volumn 217, Issue 11, 2012, Pages 1067-1079

  Karsten, Christian M ^a   Köhl, Jörg ^a,b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

B cells; Complement; Dectin 1; Fc gamma receptors; Immune complexes

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A RECEPTOR; FC RECEPTOR; FC RECEPTOR IIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BINDING AFFINITY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; DENDRITIC CELL; FOLLICULAR DENDRITIC CELL; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; NEUTROPHIL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

EID: 84866017430     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.07.015     Document Type: Review

References (190)

1. Adu D., Williams D.G. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus. Clin. Exp. Immunol. 1984, 55:495-501.
2. Agarwal S., Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr. Allergy Asthma Rep. 2009, 9:347-352.
3. Aggarwal A., Bhardwaj A., Alam S., Misra R. Evidence for activation of the alternate complement pathway in patients with juvenile rheumatoid arthritis. Rheumatology 2000, 39:189-192.
4. Ahearn J.M., Fearon D.T. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv. Immunol. 1989, 46:183-219.
5. Amara U., Flierl M.A., Rittirsch D., Klos A., Chen H., Acker B., Bruckner U.B., Nilsson B., Gebhard F., Lambris J.D., Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 2010, 185:5628-5636.
6. Anthony R.M., Wermeling F., Karlsson M.C., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:19571-19578.
7. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25:21-50.
8. Arthus M. Inections repetees de serum de cheval chez le lapin. C. R. Soc. Biol. 1903, 55:817.
9. Arya S., Chen F., Spycher S., Isenman D.E., Shulman M.J., Painter R.H. Mapping of amino acid residues in the C mu 3 domain of mouse IgM important in macromolecular assembly and complement-dependent cytolysis. J. Immunol. 1994, 152:1206-1212.
10. Atkinson J.P. C5a and Fcgamma receptors: a mutual admiration society. J. Clin. Invest. 2006, 116:304-306.
11. Ballow M., Ward G.W., Gershwin M.E., Day N.K. C1-bypass complement-activation pathway in patients with chronic urticaria and angio-oedema. Lancet 1975, 2:248-250.
12. Bandukwala H.S., Clay B.S., Tong J., Mody P.D., Cannon J.L., Shilling R.A., Verbeek J.S., Weinstock J.V., Solway J., Sperling A.I. Signaling through Fc gamma RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation. J. Exp. Med. 2007, 204:1875-1889.
13. Barb A.W., Prestegard J.H. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat. Chem. Biol. 2011, 7:147-153.
14. Barrington R.A., Pozdnyakova O., Zafari M.R., Benjamin C.D., Carroll M.C. B lymphocyte memory: role of stromal cell complement and FcgammaRIIB receptors. J. Exp. Med. 2002, 196:1189-1199.
15. Barrington R.A., Zhang M., Zhong X., Jonsson H., Holodick N., Cherukuri A., Pierce S.K., Rothstein T.L., Carroll M.C. CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses. J. Immunol. 2005, 175:2859-2867.
16. Basta M., Van Goor F., Luccioli S., Billings E.M., Vortmeyer A.O., Baranyi L., Szebeni J., Alving C.R., Carroll M.C., Berkower I., Stojilkovic S.S., Metcalfe D.D. F (ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 2003, 9:431-438.
17. Baumann U., Köhl J., Tschernig T., Schwerter-Strumpf K., Verbeek J.S., Schmidt R.E., Gessner J.E. A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J. Immunol. 2000, 164:1065-1070.
18. Biburger M., Aschermann S., Schwab I., Lux A., Albert H., Danzer H., Woigk M., Dudziak D., Nimmerjahn F. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011, 35:932-944.
19. Bokisch V.A., Müller-Eberhard H.J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 1970, 49:2427-2436.
20. Bolton W.K. Goodpasture's syndrome. Kidney Int. 1996, 50:1753-1766.
21. Bond A., Alavi A., Axford J.S., Bourke B.E., Bruckner F.E., Kerr M.A., Maxwell J.D., Tweed K.J., Weldon M.J., Youinou P., Hay F.C. A detailed lectin analysis of IgG glycosylation, demonstrating disease specific changes in terminal galactose and N-acetylglucosamine. J. Autoimmun. 1997, 10:77-85.
22. Borsos T., Rapp H.J. Complement fixation on cell surfaces by 19S and 7S antibodies. Science 1965, 150:505-506.
23. Boruchov A.M., Heller G., Veri M.C., Bonvini E., Ravetch J.V., Young J.W. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 2005, 115:2914-2923.
24. Bottazzi B., Doni A., Garlanda C., Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 2010, 28:157-183.
25. Boyd P.N., Lines A.C., Patel A.K. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 1995, 32:1311-1318.
26. Bozic C.R., Lu B., Hopken U.E., Gerard C., Gerard N.P. Neurogenic amplification of immune complex inflammation. Science 1996, 273:1722-1725.
27. Bradbury L.E., Kansas G.S., Levy S., Evans R.L., Tedder T.F. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 1992, 149:2841-2850.
28. Brekke O.H., Michaelsen T.E., Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge?. Immunol. Today 1995, 16:85-90.
29. Brockman M.A., Verschoor A., Zhu J., Carroll M.C., Knipe D.M. Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells. J. Virol. 2006, 80:7111-7117.
30. Brownlie R.J., Lawlor K.E., Niederer H.A., Cutler A.J., Xiang Z., Clatworthy M.R., Floto R.A., Greaves D.R., Lyons P.A., Smith K.G. Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J. Exp. Med. 2008, 205:883-895.
31. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012, 119:5640-5649.
32. Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113:3716-3725.
33. Burton D.R., Woof J.M. Human antibody effector function. Adv. Immunol. 1992, 51:1-84.
34. Bussel J.B. Fc receptor blockade and immune thrombocytopenic purpura. Semin. Hematol. 2000, 37:261-266.
35. Carrasco Y.R., Batista F.D. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 2007, 27:160-171.
36. Carroll M.C., Alicot E.M., Katzman P.J., Klickstein L.B., Smith J.A., Fearon D.T. Organization of the genes encoding complement receptors type 1 and 2, decay-accelerating factor, and C4-binding protein in the RCA locus on human chromosome 1. J. Exp. Med. 1988, 167:1271-1280.
37. Carter R.H., Fearon D.T. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992, 256:105-107.
38. Clynes R., Dumitru C., Ravetch J.V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998, 279:1052-1054.
39. Clynes R., Maizes J.S., Guinamard R., Ono M., Takai T., Ravetch J.V. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 1999, 189:179-185.
40. Collins C., Tsui F.W., Shulman M.J. Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur. J. Immunol. 2002, 32:1802-1810.
41. Colten H.R. Immunology. Drawing a double-edged sword. Nature 1994, 371:474-475.
42. Colten H.R., Strunk R.C. Synthesis of Complement Components in Liver and at Extraheptic Sites 1993, Kluwer Academic Publishers, Dordrecht, pp. 127-158.
43. D'Ambrosio D., Hippen K.L., Minskoff S.A., Mellman I., Pani G., Siminovitch K.A., Cambier J.C. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. Science 1995, 268:293-297.
44. Davis A.C., Roux K.H., Shulman M.J. On the structure of polymeric IgM. Eur. J. Immunol. 1988, 18:1001-1008.
45. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 1981, 20:2361-2370.
46. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996, 271:348-350.
47. Dharajiya N., Vaidya S.V., Murai H., Cardenas V., Kurosky A., Boldogh I., Sur S.A. FcgammaRIIb inhibits allergic lung inflammation in a murine model of allergic asthma. PLoS One 2010, 5:e9337.
48. Dhodapkar K.M., Kaufman J.L., Ehlers M., Banerjee D.K., Bonvini E., Koenig S., Steinman R.M., Ravetch J.V., Dhodapkar M.V. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2910-2915.
49. Dijstelbloem H.M., van de Winkel J.G., Kallenberg C.G. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol. 2001, 22:510-516.
50. Duncan A.R., Woof J.M., Partridge L.J., Burton D.R., Winter G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988, 332:563-564.
51. Fearon D.T., Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science 1996, 272:50-53.
52. Ferguson A.R., Youd M.E., Corley R.B. Marginal zone B cells transport and deposit IgM-containing immune complexes onto follicular dendritic cells. Int. Immunol. 2004, 16:1411-1422.
53. Fischer M.B., Goerg S., Shen L., Prodeus A.P., Goodnow C.C., Kelsoe G., Carroll M.C. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 1998, 280:582-585.
54. Floege J. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches?. Am. J. Kidney Dis. 2011, 58:992-1004.
55. Fujita T., Matsushita M., Endo Y. The lectin-complement pathway - its role in innate immunity and evolution. Immunol. Rev. 2004, 198:185-202.
56. Fukuyama H., Nimmerjahn F., Ravetch J.V. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat. Immunol. 2005, 6:99-106.
57. Garred P., Madsen H.O., Marquart H., Hansen T.M., Sorensen S.F., Petersen J., Volck B., Svejgaard A., Graudal N.A., Rudd P.M., Dwek R.A., Sim R.B., Andersen V. Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. J. Rheumatol. 2000, 27:26-34.
58. Gavin A.L., Barnes N., Dijstelbloem H.M., Hogarth P.M. Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J. Immunol. 1998, 160:20-23.
59. Geijtenbeek T.B., Gringhuis S.I. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 2009, 9:465-479.
60. Gerard C., Gerard N.P. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 1994, 12:775-808.
61. Ghazizadeh S., Bolen J.B., Fleit H.B. Physical and functional association of Src-related protein tyrosine kinases with Fc gamma RII in monocytic THP-1 cells. J. Biol. Chem. 1994, 269:8878-8884.
62. Ghebrehiwet B., Randazzo B.P., Dunn J.T., Silverberg M., Kaplan A.P. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J. Clin. Invest. 1983, 71:1450-1456.
63. Godau J., Heller T., Hawlisch H., Trappe M., Howells E., Best J., Zwirner J., Verbeek J.S., Hogarth P.M., Gerard C., van R.N., Klos A., Gessner J.E., Köhl J. C5a initiates the inflammatory cascade in immune complex peritonitis. J. Immunol. 2004, 173:3437-3445.
64. Gonzalez S.F., Degn S.E., Pitcher L.A., Woodruff M., Heesters B.A., Carroll M.C. Trafficking of B cell antigen in lymph nodes. Annu. Rev. Immunol. 2011, 29:215-233.
65. Gonzalez S.F., Lukacs-Kornek V., Kuligowski M.P., Pitcher L.A., Degn S.E., Turley S.J., Carroll M.C. Complement-dependent transport of antigen into B cell follicles. J. Immunol. 2010, 185:2659-2664.
66. Grant E.P., Picarella D., Burwell T., Delaney T., Croci A., Avitahl N., Humbles A.A., Gutierrez-Ramos J.C., Briskin M., Gerard C., Coyle A.J. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J. Exp. Med. 2002, 196:1461-1471.
67. Greenwood J., Clark M., Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur. J. Immunol. 1993, 23:1098-1104.
68. Gros P., Milder F.J., Janssen B.J. Complement driven by conformational changes. Nat. Rev. Immunol. 2008, 8:48-58.
69. Guddat L.W., Herron J.N., Edmundson A.B. Three-dimensional structure of a human immunoglobulin with a hinge deletion. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:4271-4275.
70. Hamaguchi Y., Xiu Y., Komura K., Nimmerjahn F., Tedder T.F. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 2006, 203:743-753.
71. Hazenbos W.L., Gessner J.E., Hofhuis F.M., Kuipers H., Meyer D., Heijnen I.A., Schmidt R.E., Sandor M., Capel P.J., Daeron M., van de Winkel J.G., Verbeek J.S. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 1996, 5:181-188.
72. Heller T., Gessner J.E., Schmidt R.E., Klos A., Bautsch W., Köhl J. Cutting edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis. J. Immunol. 1999, 162:5657-5661.
73. Heller T., Hennecke M., Baumann U., Gessner J.E., Zu Vilsendorf A.M., Baensch M., Boulay F., Kola A., Klos A., Bautsch W., Köhl J. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J. Immunol. 1999, 163:985-994.
74. Hess C., Schifferli J.A. Immune adherence revisited: novel players in an old game. News Physiol. Sci. 2003, 18:104-108.
75. Hiemstra P.S., Gorter A., Stuurman M.E., Van Es L.A., Daha M.R. Activation of the alternative pathway of complement by human serum IgA. Eur. J. Immunol. 1987, 17:321-326.
76. Hodoniczky J., Zheng Y.Z., James D.C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 2005, 21:1644-1652.
77. Holers V.M. Complement receptors and the shaping of the natural antibody repertoire. Springer Semin. Immunopathol. 2005, 26:405-423.
78. Höpken U.E., Lu B., Gerard N.P., Gerard C. Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. J. Exp. Med. 1997, 186:749-756.
79. Huber R., Deisenhofer J., Colman P.M., Matsushima M., Palm W. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 1976, 264:415-420.
80. Huber-Lang M., Denk S., Fulda S., Erler E., Kalbitz M., Weckbach S., Schneider E.M., Weiss M., Kanse S.M., Perl M. Cathepsin D is released after severe tissue trauma in vivo and is capable of generating C5a in vitro. Mol. Immunol. 2012, 50:60-65.
81. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12:682-687.
82. Huber-Lang M., Younkin E.M., Sarma J.V., Riedemann N., McGuire S.R., Lu K.T., Kunkel R., Younger J.G., Zetoune F.S., Ward P.A. Generation of C5a by phagocytic cells. Am. J. Pathol. 2002, 161:1849-1859.
83. Ioan-Facsinay A., de Kimpe S.J., Hellwig S.M., van Lent P.L., Hofhuis F.M., van Ojik H.H., Sedlik C., da Silveira S.A., Gerber J., de Jong Y.F., Roozendaal R., Aarden L.A., van den Berg W.B., Saito T., Mosser D., Amigorena S., Izui S., van Ommen G.J., van Vugt M., van de Winkel J.G., Verbeek J.S. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 2002, 16:391-402.
84. Ishizaka T., Ishizaka K., Salmon S., Fudenberg H. Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes. J. Immunol. 1967, 99:82-91.
85. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., Nilsson B., Gros P. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
86. Ji H., Ohmura K., Mahmood U., Lee D.M., Hofhuis F.M., Boackle S.A., Takahashi K., Holers V.M., Walport M., Gerard C., Ezekowitz A., Carroll M.C., Brenner M., Weissleder R., Verbeek J.S., Duchatelle V., Degott C., Benoist C., Mathis D. Arthritis critically dependent on innate immune system players. Immunity 2002, 16:157-168.
87. Junt T., Moseman E.A., Iannacone M., Massberg S., Lang P.A., Boes M., Fink K., Henrickson S.E., Shayakhmetov D.M., Di Paolo N.C., van Rooijen N., Mempel T.R., Whelan S.P., von Andrian U.H. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 2007, 450:110-114.
88. Kaneko Y., Nimmerjahn F., Madaio M.P., Ravetch J.V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 2006, 203:789-797.
89. Karsten, C.M., Pandey, M.K., Figge, J., Kilchenstein, R., Taylor, P.R., Rosas, M., McDonald, J.U., Orr, S., Berger, M., Petzold, D., Blanchard, V., Winkler, A., Hess, C., Reid, D.M., Majoul, I.V., Strait, R.T., Harris, N.L., Köhl, G., Wex, E., Ludwig, R., Zillikens, D., Nimmerjahn, F., Finkelman, F.D., Brown, G.D., Ehlers, M., Köhl, J. Galactosylated IgG1 links FcgRIIB and Dectin-1 to block complement-mediated inflammation. Nat. Med., in press.
90. Kiener P.A., Rankin B.M., Burkhardt A.L., Schieven G.L., Gilliland L.K., Rowley R.B., Bolen J.B., Ledbetter J.A. Cross-linking of Fc gamma receptor I (Fc gamma RI) and receptor II (Fc gamma RII) on monocytic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase. J. Biol. Chem. 1993, 268:24442-24448.
91. Kim H.Y., Kim S., Chung D.H. FcgammaRIII engagement provides activating signals to NKT cells in antibody-induced joint inflammation. J. Clin. Invest. 2006, 116:2484-2492.
92. Klaus G.G., Pepys M.B., Kitajima K., Askonas B.A. Activation of mouse complement by different classes of mouse antibody. Immunology 1979, 38:687-695.
93. Klein M., Haeffner-Cavaillon N., Isenman D.E., Rivat C., Navia M.A., Davies D.R., Dorrington K.J. Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:524-528.
94. Klein M.A., Kaeser P.S., Schwarz P., Weyd H., Xenarios I., Zinkernagel R.M., Carroll M.C., Verbeek J.S., Botto M., Walport M.J., Molina H., Kalinke U., Acha-Orbea H., Aguzzi A. Complement facilitates early prion pathogenesis. Nat. Med. 2001, 7:488-492.
95. Knutzen Steuer K.L., Sloan L.B., Oglesby T.J., Farries T.C., Nickells M.W., Densen P., Harley J.B., Atkinson J.P. Lysis of sensitized sheep erythrocytes in human sera deficient in the second component of complement. J. Immunol. 1989, 143:2256-2261.
96. Kobata A. The N-linked sugar chains of human immunoglobulin G: their unique pattern, and their functional roles. Biochim. Biophys. Acta 2008, 1780:472-478.
97. Köhl J. The role of complement in danger sensing and transmission. Immunol. Res. 2006, 34:157-176.
98. Koide N., Nose M., Muramatsu T. Recognition of IgG by Fc receptor and complement: effects of glycosidase digestion. Biochem. Biophys. Res. Commun. 1977, 75:838-844.
99. Konrad S., Ali S.R., Wiege K., Syed S.N., Engling L., Piekorz R.P., Hirsch E., Nurnberg B., Schmidt R.E., Gessner J.E. Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation. J. Biol. Chem. 2008, 283:33296-33303.
100. Konrad S., Baumann U., Schmidt R.E., Gessner J.E. Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages. Br. J. Haematol. 2006, 134:345-347.
101. Korganow A.S., Ji H., Mangialaio S., Duchatelle V., Pelanda R., Martin T., Degott C., Kikutani H., Rajewsky K., Pasquali J.L., Benoist C., Mathis D. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999, 10:451-461.
102. Kouskoff V., Korganow A.S., Duchatelle V., Degott C., Benoist C., Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell 1996, 87:811-822.
103. Kovacsovics T., Tschopp J., Kress A., Isliker H. Antibody-independent activation of C1, the first component of complement, by cardiolipin. J. Immunol. 1985, 135:2695-2700.
104. Kulics J., Rajnavolgyi E., Fust G., Gergely J. Interaction of C3 and C3b with immunoglobulin G. Mol. Immunol. 1983, 20:805-810.
105. Kumar V., Ali S.R., Konrad S., Zwirner J., Verbeek J.S., Schmidt R.E., Gessner J.E. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J. Clin. Invest. 2006, 116:512-520.
106. Kurtz C.B., O'Toole E., Christensen S.M., Weis J.H. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J. Immunol. 1990, 144:3581-3591.
107. Lutz H.U., Jelezarova E. Complement amplification revisited. Mol. Immunol. 2006, 43:2-12.
108. Madaio M.P. The role of autoantibodies in the pathogenesis of lupus nephritis. Semin. Nephrol. 1999, 19:48-56.
109. Malhotra R., Wormald M.R., Rudd P.M., Fischer P.B., Dwek R.A., Sim R.B. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1995, 1:237-243.
110. Matsushita M., Okada H. Alternative complement pathway activation by C4b deposited during classical pathway activation. J. Immunol. 1986, 136:2994-2998.
111. Matthews K.W., Mueller-Ortiz S.L., Wetsel R.A. Carboxypeptidase N: a pleiotropic regulator of inflammation. Mol. Immunol. 2004, 40:785-793.
112. May J.E., Frank M.M. Hemolysis of sheep erythrocytes in guinea pig serum deficient in the fourth component of complement. I. Antibody and serum requirements. J. Immunol. 1973, 111:1671-1677.
113. May J.E., Frank M.M. Hemolysis of sheep erythrocytes in guinea pig serum deficient in the fourth component of complement. II. Evidence for involvement of C1 and components of the alternate complement pathway. J. Immunol. 1973, 111:1668-1676.
114. May J.E., Frank M.M. A new complement-mediated cytolytic mechanism - the C1-bypass activation pathway. Proc. Natl. Acad. Sci. U.S.A. 1973, 70:649-652.
115. McGaha T.L., Sorrentino B., Ravetch J.V. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005, 307:590-593.
116. Molina H., Kinoshita T., Inoue K., Carel J.C., Holers V.M. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J. Immunol. 1990, 145:2974-2983.
117. Molina H., Kinoshita T., Webster C.B., Holers V.M. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2. J. Immunol. 1994, 153:789-795.
118. Nardin A., Lindorfer M.A., Taylor R.P. How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells?. Mol. Immunol. 1999, 36:827-835.
119. Nimmerjahn F., Lux A., Albert H., Woigk M., Lehmann C., Dudziak D., Smith P., Ravetch J.V. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:19396-19401.
120. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
121. Nimmerjahn F., Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 2006, 24:19-28.
122. Nimmerjahn F., Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 2007, 204:11-15.
123. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 2008, 26:513-533.
124. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
125. Nolin L., O'Regan S., Pelletier M., Rivard G.E., Mongeau J.G., Robitaille P. Possible C1q bypass loop activation in the haemolytic uraemic syndrome. Clin. Exp. Immunol. 1979, 35:107-111.
126. Nonaka M., Kimura A. Genomic view of the evolution of the complement system. Immunogenetics 2006, 58:701-713.
127. Norderhaug L., Brekke O.H., Bremnes B., Sandin R., Aase A., Michaelsen T.E., Sandlie I. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge. Eur. J. Immunol. 1991, 21:2379-2384.
128. Nose M., Wigzell H. Biological significance of carbohydrate chains on monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:6632-6636.
129. Nussenzweig V., Bianco C., Dukor P., Eden A. Receptors for C3 on B Lymphocytes: Possible Role in the Immune System 1971, Academic Press, pp. 73-81.
130. Odin J.A., Edberg J.C., Painter C.J., Kimberly R.P., Unkeless J.C. Regulation of phagocytosis and [Ca2+]i flux by distinct regions of an Fc receptor. Science 1991, 254:1785-1788.
131. Ono M., Bolland S., Tempst P., Ravetch J.V. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc (gamma)RIIB. Nature 1996, 383:263-266.
132. Ono M., Okada H., Bolland S., Yanagi S., Kurosaki T., Ravetch J.V. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell 1997, 90:293-301.
133. Oortwijn B.D., Eijgenraam J.W., Rastaldi M.P., Roos A., Daha M.R., van Kooten C. The role of secretory IgA and complement in IgA nephropathy. Semin. Nephrol. 2008, 28:58-65.
134. Pangburn M.K., Müller-Eberhard H.J. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J. Exp. Med. 1980, 152:1102-1114.
135. Pangburn M.K., Schreiber R.D., Müller-Eberhard H.J. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med. 1981, 154:856-867.
136. Papamichail M., Gutierrez C., Embling P., Johnson P., Holborow E.J., Pepys M.B. Complement dependence of localisation of aggregated IgG in germinal centres. Scand. J. Immunol. 1975, 4:343-347.
137. Parekh R., Isenberg D., Rook G., Roitt I., Dwek R., Rademacher T. A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J. Autoimmun. 1989, 2:101-114.
138. Parekh R.B., Dwek R.A., Sutton B.J., Fernandes D.L., Leung A., Stanworth D., Rademacher T.W., Mizuochi T., Taniguchi T., Matsuta K., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985, 316:452-457.
139. Park S.Y., Ueda S., Ohno H., Hamano Y., Tanaka M., Shiratori T., Yamazaki T., Arase H., Arase N., Karasawa A., Sato S., Ledermann B., Kondo Y., Okumura K., Ra C., Saito T. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J. Clin. Invest. 1998, 102:1229-1238.
140. Parker C.J. Paroxysmal nocturnal hemoglobinuria. Curr. Opin. Hematol. 2012, 19:141-148.
141. Parren P.W., Warmerdam P.A., Boeije L.C., Arts J., Westerdaal N.A., Vlug A., Capel P.J., Aarden L.A., van de Winkel J.G. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J. Clin. Invest. 1992, 90:1537-1546.
142. Paul E., Nelde A., Verschoor A., Carroll M.C. Follicular exclusion of autoreactive B cells requires FcgammaRIIb. Int. Immunol. 2007, 19:365-373.
143. Peitsch M.C., Tschopp J., Kress A., Isliker H. Antibody-independent activation of the complement system by mitochondria is mediated by cardiolipin. Biochem. J. 1988, 249:495-500.
144. Perkins S.J., Nealis A.S., Sutton B.J., Feinstein A. Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. J. Mol. Biol. 1991, 221:1345-1366.
145. Petrusic V., Zivkovic I., Stojanovic M., Stojicevic I., Marinkovic E., Dimitrijevic L. Hexameric immunoglobulin M in humans: desired or unwanted?. Med. Hypotheses 2011, 77:959-961.
146. Phan T.G., Green J.A., Gray E.E., Xu Y., Cyster J.G. Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat. Immunol. 2009, 10:786-793.
147. Phan T.G., Grigorova I., Okada T., Cyster J.G. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat. Immunol. 2007, 8:992-1000.
148. Pozdnyakova O., Guttormsen H.K., Lalani F.N., Carroll M.C., Kasper D.L. Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J. Immunol. 2003, 170:84-90.
149. Raby A.C., Holst B., Davies J., Colmont C., Laumonnier Y., Coles B., Shah S., Hall J., Topley N., Kohl J., Morgan B.P., Labeta M.O. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. Eur. J. Immunol. 2011, 41:2741-2752.
150. Raju T.S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 2008, 20:471-478.
151. Rankin B.M., Yocum S.A., Mittler R.S., Kiener P.A. Stimulation of tyrosine phosphorylation and calcium mobilization by Fc gamma receptor cross-linking. Regulation by the phosphotyrosine phosphatase CD45. J. Immunol. 1993, 150:605-616.
152. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
153. Riedemann N.C., Guo R.F., Neff T.A., Laudes I.J., Keller K.A., Sarma V.J., Markiewski M.M., Mastellos D., Strey C.W., Pierson C.L., Lambris J.D., Zetoune F.S., Ward P.A. Increased C5a receptor expression in sepsis. J. Clin. Invest. 2002, 110:101-108.
154. Roos A., Bouwman L.H., van Gijlswijk-Janssen D.J., Faber-Krol M.C., Stahl G.L., Daha M.R. Human IgA activates the complement system via the mannan-binding lectin pathway. J. Immunol. 2001, 167:2861-2868.
155. Roos A., Rastaldi M.P., Calvaresi N., Oortwijn B.D., Schlagwein N., van Gijlswijk-Janssen D.J., Stahl G.L., Matsushita M., Fujita T., van Kooten C., Daha M.R. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J. Am. Soc. Nephrol. 2006, 17:1724-1734.
156. Royle L., Roos A., Harvey D.J., Wormald M.R., van Gijlswijk-Janssen D., Redwan el R.M., Wilson I.A., Daha M.R., Dwek R.A., Rudd P.M. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J. Biol. Chem. 2003, 278:20140-20153.
157. Sahu A., Kozel T.R., Pangburn M.K. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem. J. 1994, 302(Pt 2):429-436.
158. Schur P.H., Christian G.D. The role of disulfide bonds in the complement-fixing and precipitating properties of 7s rabbit and sheep antibodies. J. Exp. Med. 1964, 120:531-545.
159. Schwaeble W.J., Reid K.B. Does properdin crosslink the cellular and the humoral immune response?. Immunol. Today 1999, 20:17-21.
160. Shohet J.M., Pemberton P., Carroll M.C. Identification of a major binding site for complement C3 on the IgG1 heavy chain. J. Biol. Chem. 1993, 268:5866-5871.
161. Shulman M.J., Collins C., Pennell N., Hozumi N. Complement activation by IgM: evidence for the importance of the third constant domain of the mu heavy chain. Eur. J. Immunol. 1987, 17:549-554.
162. Shushakova N., Skokowa J., Schulman J., Baumann U., Zwirner J., Schmidt R.E., Gessner J.E. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J. Clin. Invest. 2002, 110:1823-1830.
163. Silverton E.W., Navia M.A., Davies D.R. Three-dimensional structure of an intact human immunoglobulin. Proc. Natl. Acad. Sci. U.S.A. 1977, 74:5140-5144.
164. Skattum L., van Deuren M., van der Poll T., Truedsson L. Complement deficiency states and associated infections. Mol. Immunol. 2011, 48:1643-1655.
165. Skokowa J., Ali S.R., Felda O., Kumar V., Konrad S., Shushakova N., Schmidt R.E., Piekorz R.P., Nurnberg B., Spicher K., Birnbaumer L., Zwirner J., Claassens J.W., Verbeek J.S., van R.N., Köhl J., Gessner J.E. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J. Immunol. 2005, 174:3041-3050.
166. Storrs S.B., Kolb W.P., Olson M.S. C1q binding and C1 activation by various isolated cellular membranes. J. Immunol. 1983, 131:416-422.
167. Syed S.N., Konrad S., Wiege K., Nieswandt B., Nimmerjahn F., Schmidt R.E., Gessner J.E. Both FcgammaRIV and FcgammaRIII are essential receptors mediating type II and type III autoimmune responses via FcRgamma-LAT-dependent generation of C5a. Eur. J. Immunol. 2009, 39:3343-3356.
168. Sylvestre D.L., Ravetch J.V. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 1994, 265:1095-1098.
169. Tack B.F., Harrison R.A., Janatova J., Thomas M.L., Prahl J.W. Evidence for presence of an internal thiolester bond in third component of human complement. Proc. Natl. Acad. Sci. U.S.A. 1980, 77:5764-5768.
170. Takai T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2002, 2:580-592.
171. Takai T., Li M., Sylvestre D., Clynes R., Ravetch J.V. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994, 76:519-529.
172. Takai T., Ono M., Hikida M., Ohmori H., Ravetch J.V. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1996, 379:346-349.
173. Tan L.K., Shopes R.J., Oi V.T., Morrison S.L. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:162-166.
174. Tao M.H., Canfield S.M., Morrison S.L. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J. Exp. Med. 1991, 173:1025-1028.
175. Tao M.H., Smith R.I., Morrison S.L. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 1993, 178:661-667.
176. Thiel S., Gadjeva M. Humoral pattern recognition molecules: mannan-binding lectin and ficolins. Adv. Exp. Med. Biol. 2009, 653:58-73.
177. Thommesen J.E., Michaelsen T.E., Loset G.A., Sandlie I., Brekke O.H. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation. Mol. Immunol. 2000, 37:995-1004.
178. Traustadottir K.H., Rafnar B.O., Steinsson K., Valdimarsson H., Erlendsson K. Participation of factor B in residual immune complex red cell binding activity observed in serum from a C2-deficient systemic lupus erythematosus patient may delay the appearance of clinical symptoms. Arthritis Rheum. 1998, 41:427-434.
179. Tsuchiya N., Endo T., Matsuta K., Yoshinoya S., Aikawa T., Kosuge E., Takeuchi F., Miyamoto T., Kobata A. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J. Rheumatol. 1989, 16:285-290.
180. Tsuchiya N., Kyogoku C. Role of Fc gamma receptor IIb polymorphism in the genetic background of systemic lupus erythematosus: insights from Asia. Autoimmunity 2005, 38:347-352.
181. Utsumi S., Okada M., Udaka K., Amano T. Preparation and biologic characterization of fragments containing dimeric and monomeric C gamma 2 domain of rabbit IgG. Mol. Immunol. 1985, 22:811-819.
182. van de Winkel J.G., Capel P.J. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 1993, 14:215-221.
183. van der Poel C.E., Spaapen R.M., van de Winkel J.G., Leusen J.H. Functional characteristics of the high affinity IgG receptor, FcgammaRI. J. Immunol. 2011, 186:2699-2704.
184. Wagner E., Platt J.L., Howell D.N., Marsh H.C., Frank M.M. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model. J. Immunol. 1999, 163:3549-3558.
185. Wang A.V., Scholl P.R., Geha R.S. Physical and functional association of the high affinity immunoglobulin G receptor (Fc gamma RI) with the kinases Hck and Lyn. J. Exp. Med. 1994, 180:1165-1170.
186. Williams R.C., Osterland C.K., Margherita S., Tokuda S., Messner R.P. Studies of biologic and serologic activities of rabbit-IgG antibody depleted of carbohydrate residues. J. Immunol. 1973, 111:1690-1698.
187. Wright A., Morrison S.L. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J. Exp. Med. 1994, 180:1087-1096.
188. Xiang Z., Cutler A.J., Brownlie R.J., Fairfax K., Lawlor K.E., Severinson E., Walker E.U., Manz R.A., Tarlinton D.M., Smith K.G. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 2007, 8:419-429.
189. Xu Y., Oomen R., Klein M.H. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement. J. Biol. Chem. 1994, 269:3469-3474.
190. Youd M.E., Ferguson A.R., Corley R.B. Synergistic roles of IgM and complement in antigen trapping and follicular localization. Eur. J. Immunol. 2002, 32:2328-2337.